Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis

BACKGROUND AND AIMS: A considerable number of patients with ulcerative colitis (UC) who initially respond to golimumab (GLM), an anti-TNF-α antibody, gradually lose clinical response. Therapeutic drug monitoring has been proposed to optimize serum anti-TNF-α antibody concentrations before the loss o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawa, Hideki, Kakimoto, Kazuki, Numa, Keijiro, Kinoshita, Naohiko, Kawasaki, Yuka, Tatsumi, Yoshihiro, Koshiba, Ryoji, Nakata, Satoshi, Hirata, Yuki, Ota, Kazuhiro, Sakiyama, Naokuni, Kojima, Yuichi, Koubayashi, Eiko, Nishikawa, Hiroki, Takeuchi, Toshihisa, Inoue, Takuya, Fukunishi, Shinya, Miyazaki, Takako, Nakamura, Shiro, Higuchi, Kazuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932821/
https://www.ncbi.nlm.nih.gov/pubmed/35697000
http://dx.doi.org/10.1159/000524593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932821/
https://www.ncbi.nlm.nih.gov/pubmed/35697000
http://dx.doi.org/10.1159/000524593

Ejemplares similares